CBMG Out-Licenses Top Two CAR-T Candidates to Janssen for $245 Million Upfront

Cellular Biomedicine Group (CMBG), a Maryland cell therapy company with a China arm, out-licensed global rights (ex-China) for its two lead CAR-T candidates to Janssen Biotech for $245 million upfront plus milestones. Janssen has the right to negotiate for China rights before CBMG files a BLA in China for the candidates. The agreement includes C-CAR039, an anti-CD19 & CD20 bi-specific CAR-T therapy, and C-CAR066, an anti-CD20 CAR-T. Both candidates have started trials for Non-Hodgkin Lymphoma. In 2020, CMBG’s management took the company private in a $385 million privatization. More details...